17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta‐Analysis, and New Insights From the CLOSE Study

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          We conducted a systematic review and meta‐analysis of randomized controlled trials ( RCTs) comparing patent foramen ovale ( PFO) closure, anticoagulation, and antiplatelet therapy to prevent stroke recurrence in patients with PFO‐associated cryptogenic stroke.

          Methods and Results

          We searched Medline, Cochrane Library, and EMBASE through March 2018. The primary outcome was stroke recurrence. Pooled incidences, hazard ratios, and risk ratios ( RRs) were calculated in random‐effects meta‐analyses. PFO closure was associated with a lower risk of recurrent stroke compared with antithrombotic therapy (antiplatelet therapy or anticoagulation: 3560 patients from 6 RCTs; RR=0.36, 95% CI: 0.17–0.79; I 2=59%). The effect of PFO closure on stroke recurrence was larger in patients with atrial septal aneurysm or large shunt ( RR=0.27, 95% CI, 0.11–0.70; I 2=42%) compared with patients without these anatomical features ( RR=0.80, 95% CI, 0.43–1.47; I 2=12%). Major complications occurred in 2.40% (95% CI, 1.03–4.25; I 2=77%) of procedures. New‐onset atrial fibrillation was more frequent in patients randomized to PFO closure versus antithrombotic therapy ( RR=4.33, 95% CI, 2.37–7.89; I 2=14%). One RCT compared PFO closure versus anticoagulation (353 patients; hazard ratio=0.14, 95% CI, 0.00–1.45) and 2 RCTs compared PFO closure versus antiplatelet therapy (1137 patients; hazard ratio=0.18, 95% CI, 0.05–0.63; I 2=12%). Three RCTs compared anticoagulation versus antiplatelet therapy, with none showing a significant difference.

          Conclusions

          PFO closure is superior to antithrombotic therapy to prevent stroke recurrence after cryptogenic stroke. The annual absolute risk reduction of stroke was low, but it has to be tempered by a substantial time at risk (at least 5 years) in young and middle‐aged patients. PFO closure was associated with an increased risk of atrial fibrillation.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke

          Trials of patent foramen ovale (PFO) closure to prevent recurrent stroke have been inconclusive. We investigated whether patients with cryptogenic stroke and echocardiographic features representing risk of stroke would benefit from PFO closure or anticoagulation, as compared with antiplatelet therapy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke

            The efficacy of closure of a patent foramen ovale (PFO) in the prevention of recurrent stroke after cryptogenic stroke is uncertain. We investigated the effect of PFO closure combined with antiplatelet therapy versus antiplatelet therapy alone on the risks of recurrent stroke and new brain infarctions.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke

              Whether closure of a patent foramen ovale reduces the risk of recurrence of ischemic stroke in patients who have had a cryptogenic ischemic stroke is unknown.
                Bookmark

                Author and article information

                Contributors
                jl.mas@ch-sainte-anne.fr
                Journal
                J Am Heart Assoc
                J Am Heart Assoc
                10.1002/(ISSN)2047-9980
                JAH3
                ahaoa
                Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
                John Wiley and Sons Inc. (Hoboken )
                2047-9980
                17 June 2018
                19 June 2018
                : 7
                : 12 ( doiID: 10.1002/jah3.2018.7.issue-12 )
                : e008356
                Affiliations
                [ 1 ] Department of Neurology Hôpital Sainte‐Anne Paris France
                [ 2 ] Université Paris Descartes Sorbonne Paris Cité Paris France
                [ 3 ] NSERM U894 Paris France
                [ 4 ] DHU Neurovasc Paris France
                [ 5 ] Department of Cardiology INSERM UMR 915 Institut du Thorax Nantes France
                [ 6 ] Institut du Thorax Centre Hospitalier Universitaire de Nantes Nantes France
                [ 7 ] Department of Cardiology Cochin Hospital APHP Paris France
                [ 8 ] Epidemiology and Clinical Research Unit Georges Pompidou European Hospital APHP Paris France
                [ 9 ] INSERM CIC 1418 Paris France
                Author notes
                [*] [* ] Correspondence to: Jean‐Louis Mas, MD, Service de Neurologie, Hôpital Sainte‐Anne, 1 rue Cabanis, 75014 Paris, France. E‐mail: jl.mas@ 123456ch-sainte-anne.fr
                [†]

                A complete list of the CLOSE investigators is given in Appendix  S1.

                Article
                JAH33203
                10.1161/JAHA.117.008356
                6220551
                29910193
                a0b6b371-c8b3-4b3a-80ab-933394239a08
                © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 12 December 2017
                : 11 April 2018
                Page count
                Figures: 4, Tables: 1, Pages: 12, Words: 8583
                Funding
                Funded by: French Ministry of Health
                Categories
                Systematic Review and Meta‐Analysis
                Systematic Review and Meta‐Analysis
                Custom metadata
                2.0
                jah33203
                19 June 2018
                Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.4.1.1 mode:remove_FC converted:19.06.2018

                Cardiovascular Medicine
                anticoagulation,patent foramen ovale,patent foramen ovale closure,stroke,anticoagulants,secondary prevention,meta analysis,ischemic stroke

                Comments

                Comment on this article